Bastion Biologics is a biotech startup, developing polymer antibody conjugate platform with a unique mechanism of action to crosslink cell receptors, to design safer drugs targeting cancers, autoimmune and neurologic disorders.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bastion-biologics” connections=”true” suffix=””]

Bastions PolyFab technology allows to create molecules crosslinks on target cell membrane.
A small antigen targeting antibody fragment is attached to a DNA-thread like fragment (MORF1) to create a targeting scaffold (Fab-MORF1) and is injected into the bloodstream to bind the target cell receptor. And is followed by injection of polymer based P-MORF2 (to enhance signal) into the bloodstream, which attaches to multiple Fab-MORF1 at the cell surface. This causes target receptors to crosslink. Binding of P-MORF2 to Fab-MORF1 is the therapeutically active step.Crosslinking of cell receptors sends a signal downstream to engage pathways within the cell. These signals can cause cell suicide or immune system activation.